BACKGROUND: We showed recently that limb allograft survival could be enhanced by administration of alloantigen (Ag)-pulsed immature dendritic cells (DC) after transplantation. Since indefinite graft survival was not achieved, we have further modified the DC by pharmacologic (rapamycin; Rapa) conditioning and ascertained their influence on graft survival, without continued immunosuppressive therapy. METHODS: We compared the ability of donor Ag-pulsed, Rapa-conditioned rat myeloid DC (Rapa DC) and control DC (CTR DC) to inhibit alloreactive T-cell responses after limb transplantation in antilymphocyte serum (ALS)-treated recipients given a short postoperative course of cyclosporine (CsA). RESULTS: Both DC populations expressed similar levels of major histocompatibility complex (MHC) II, CD40 and CD54, but Rapa DC expressed lower CD86. After toll-like receptor activation, both populations produced minimal interleukin (IL)-12p70, but Rapa DC secreted lower levels of IL-6 and IL-10. The capacity of DCs to stimulate T-cell proliferation in mixed leukocyte reactions was very low. Pulsing of the DC with donor Ag did not alter their phenotype or function. Interestingly, posttransplant administration of donor Ag-pulsed Rapa DC to rats given perioperative ALS and 21 days CsA significantly delayed graft rejection and promoted long-term (>125 days) graft survival. AlloAg-pulsed Rapa DC induced T-cell hyporesponsiveness and promoted the generation of IL-10-secreting CD4 T cells upon ex vivo challenge. CONCLUSIONS: Infusion of donor Ag-pulsed, Rapa-conditioned DC after composite tissue transplantation can prevent rejection of the grafts, including skin, across a full MHC mismatch and in the absence of continued immunosuppressive therapy.
BACKGROUND: We showed recently that limb allograft survival could be enhanced by administration of alloantigen (Ag)-pulsed immature dendritic cells (DC) after transplantation. Since indefinite graft survival was not achieved, we have further modified the DC by pharmacologic (rapamycin; Rapa) conditioning and ascertained their influence on graft survival, without continued immunosuppressive therapy. METHODS: We compared the ability of donor Ag-pulsed, Rapa-conditioned rat myeloid DC (Rapa DC) and control DC (CTR DC) to inhibit alloreactive T-cell responses after limb transplantation in antilymphocyte serum (ALS)-treated recipients given a short postoperative course of cyclosporine (CsA). RESULTS: Both DC populations expressed similar levels of major histocompatibility complex (MHC) II, CD40 and CD54, but Rapa DC expressed lower CD86. After toll-like receptor activation, both populations produced minimal interleukin (IL)-12p70, but Rapa DC secreted lower levels of IL-6 and IL-10. The capacity of DCs to stimulate T-cell proliferation in mixed leukocyte reactions was very low. Pulsing of the DC with donor Ag did not alter their phenotype or function. Interestingly, posttransplant administration of donor Ag-pulsed Rapa DC to rats given perioperative ALS and 21 days CsA significantly delayed graft rejection and promoted long-term (>125 days) graft survival. AlloAg-pulsed Rapa DC induced T-cell hyporesponsiveness and promoted the generation of IL-10-secreting CD4 T cells upon ex vivo challenge. CONCLUSIONS: Infusion of donor Ag-pulsed, Rapa-conditioned DC after composite tissue transplantation can prevent rejection of the grafts, including skin, across a full MHC mismatch and in the absence of continued immunosuppressive therapy.
Authors: M B Ezzelarab; D Raich-Regue; L Lu; A F Zahorchak; A Perez-Gutierrez; A Humar; M Wijkstrom; M Minervini; R W Wiseman; D K C Cooper; A E Morelli; A W Thomson Journal: Am J Transplant Date: 2017-02-02 Impact factor: 8.086
Authors: Ryan T Fischer; Hēth R Turnquist; Zhiliang Wang; Donna Beer-Stolz; Angus W Thomson Journal: Transpl Immunol Date: 2011-05-10 Impact factor: 1.708
Authors: A W Thomson; J M Sacks; Y-R Kuo; R Ikeguchi; E K Horibe; J Unadkat; M G Solari; M Feili-Hariri; W P A Lee Journal: Transplant Proc Date: 2009-03 Impact factor: 1.066
Authors: C Macedo; H R Turnquist; M Castillo-Rama; A F Zahorchak; R Shapiro; A W Thomson; D Metes Journal: Am J Transplant Date: 2013-08-22 Impact factor: 8.086
Authors: M B Ezzelarab; A F Zahorchak; L Lu; A E Morelli; G Chalasani; A J Demetris; F G Lakkis; M Wijkstrom; N Murase; A Humar; R Shapiro; D K C Cooper; A W Thomson Journal: Am J Transplant Date: 2013-06-11 Impact factor: 8.086
Authors: David W Mathes; Marie Noland; Scott Graves; Robert Schlenker; Tiffany Miwongtum; Rainer Storb Journal: J Reconstr Microsurg Date: 2010-01-27 Impact factor: 2.873